Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioequivalence Methods For Modified-Release Drugs To Be Examined By USP

Executive Summary

The U.S. Pharmacopeia plans to take a role in developing bioequivalence methods for modified- and immediate-release drugs.

You may also be interested in...



Biologic Monographs Could Hinder Follow-On Products – USP CEO Williams

Published monographs for biologics could hinder the development of follow-on products, United States Pharmacopeia CEO Roger Williams, MD, said

Biologic Monographs Could Hinder Follow-On Products – USP CEO Williams

Published monographs for biologics could hinder the development of follow-on products, United States Pharmacopeia CEO Roger Williams, MD, said

Generic Biologic Science Must Evolve Before Legislative Debate – Lumpkin

FDA and industry need to work out the science of generic biologics before a legislative debate would be useful, FDA Principle Associate Commissioner Murray Lumpkin, MD, suggested

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel